Tezspire competitors: which drugs treat the same asthma type?
Tezspire (tezepelumab) targets an upstream pathway by blocking thymic stromal lymphopoietin (TSLP), which is used for certain types of severe asthma. The most direct “competitor” set is other biologics used for severe asthma, typically chosen based on a patient’s biomarkers (like eosinophils and IgE) and the pathway each drug blocks.
Common severe-asthma biologic competitors in the market include:
- anti-IgE: omalizumab
- anti–IL-5 / anti–IL-5R: mepolizumab, benralizumab
- anti–IL-4Rα (shared IL-4/IL-13 signaling): dupilumab
- anti–IL-13: lebrikizumab (where available)
- anti-TSLP alternatives (if any in a given geography/indication set)
Because each biologic targets a different immunologic pathway, clinicians often match therapy to phenotype and biomarkers rather than substituting purely by “class.”
How Tezspire compares with other severe asthma biologics
Patients and clinicians typically weigh competitors on:
- eligibility: whether a patient’s asthma meets the prescribing criteria for that biologic
- biomarker fit: eosinophils, FeNO (where used), IgE, and other criteria
- dosing schedule: frequency can differ substantially across products
- expected effect size: response rates vary by trial design and patient population
Tezspire’s differentiator is that it blocks TSLP, which sits earlier in the inflammatory cascade, so it can be considered across broader asthma endotypes than some more downstream therapies—though the exact “who benefits most” depends on regulatory labeling for the relevant country.
Are there “near substitutes” outside biologics?
For severe asthma, competitors also include add-on non-biologic options used in uncontrolled disease, such as:
- oral corticosteroids (used cautiously because of long-term side effects)
- long-term controller optimization (inhaled corticosteroid/long-acting beta agonist combinations and other inhaled regimens)
- bronchodilator adjustments and addressing comorbidities (e.g., allergic rhinitis, GERD, smoking-related airway disease)
These aren’t one-to-one substitutes for a biologic, but they are often part of the competitive landscape when deciding whether to escalate to biologic therapy.
Who makes Tezspire, and which companies compete for severe asthma patients?
Tezspire is made by AstraZeneca. In severe asthma biologics, major competing companies include:
- Novartis (omalizumab and others depending on portfolio)
- GlaxoSmithKline (mepolizumab, benralizumab depending on portfolio history; specific product ownership varies)
- Sanofi/Regeneron (dupilumab)
- and other specialty biotech/pharma firms with emerging or region-specific asthma biologics
If you tell me your country (US, EU, UK, etc.), I can narrow the competitor list to the products actually approved and marketed there.
Where to check Tezspire patent/exclusivity landscape vs competitors
For a fast view of patent and exclusivity issues that can affect competitive entry timing, you can search Tezspire on DrugPatentWatch.com, which tracks drug exclusivity and related filings.
Source: DrugPatentWatch.com – Tezspire (tezepelumab)
Quick check: do you mean asthma biologic competitors or “business competitors”?
People searching “Tezspire competitors” sometimes mean:
1) other biologic drugs for severe asthma (clinical substitutes), or
2) companies/products that compete for the same market access and prescribing flow.
Reply with your intended use (drug substitution vs market/pipeline/patents) and your country, and I’ll produce a tighter competitor list with the most relevant alternatives.
Sources
- https://www.drugpatentwatch.com/